文献速递淋巴瘤

检查点阻断治疗使复发/难治性非霍奇金淋巴瘤对后续治疗敏感

Checkpoint blockade treatment sensitises relapsed/refractory non-Hodgkin lymphoma to subsequent therapy.
PubMed 文献 · Br J Haematol · 2020-05-19

这项回顾性多中心分析纳入59例复发/难治性非霍奇金淋巴瘤患者,评估检查点阻断治疗(CBT)后后续治疗的总体缓解率(ORR)。CBT后治疗的ORR为51%,中位无进展生存期6.1个月;对CBT后治疗至少达疾病稳定的患者,中位缓解持续时间显著长于CBT前(310天 vs 79天,P=0.005),提示致敏作用。

要点

  • CBT后治疗的ORR为51%,中位PFS为6.1个月。
  • 对CBT后治疗至少达SD者,中位DOR较CBT前显著延长(310天 vs 79天,P=0.005)。
  • 59例中53例(90%)因疾病进展停用CBT,19例在CBT后治疗后续接受移植。

核心结论

  • 复发/难治性非霍奇金淋巴瘤患者CBT后后续治疗的ORR为51%,中位PFS为6.1个月。
  • 对CBT后治疗至少达疾病稳定的患者,中位DOR较CBT前显著延长(310天 vs 79天,P=0.005),提示致敏作用。
  • 中位总生存期未达到,且不受治疗方案影响。
  • 原文结论提出需开展前瞻性试验,这可能为复发/难治性非霍奇金淋巴瘤患者提供新的治疗途径。

研究设计与样本

  • 十七个北美中心回顾性查询记录,进行CBT对后续非霍奇金淋巴瘤治疗影响的首次分析。
  • 主要目的为评估CBT后治疗的总体缓解率(ORR),次要目的包括无进展生存期(PFS)、缓解持续时间(DOR)和总生存期(OS)。
  • 纳入59例患者,其中68%为侵袭性非霍奇金淋巴瘤,69%为晚期疾病。
  • 患者在CBT前接受中位三种治疗。

主要发现

  • 53例(90%)因疾病进展停用CBT。
  • CBT后方案包括化疗(49%)、靶向治疗(30%)、临床试验(17%)、移植预处理(2%)和嵌合抗原受体T细胞(CAR-T)治疗(2%)。
  • CBT后治疗的ORR为51%,中位PFS为6.1个月。
  • 对CBT后治疗至少达疾病稳定的患者,中位DOR为310天,CBT前为79天(P=0.005)。
  • 19例在CBT后治疗后续接受移植;中位总生存期未达到,且不受治疗方案影响。

临床怎么用

  • 原文结论提出需开展前瞻性试验,这可能为复发/难治性非霍奇金淋巴瘤患者提供新的治疗途径。

局限性

  • 原文为回顾性查询记录的研究设计。
  • 原文结论提出需开展前瞻性试验。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Patients with relapsed/refractory (R/R) non-Hodgkin lymphoma (NHL) have limited options for salvage, and checkpoint blockade therapy (CBT) has little efficacy. Usage in solid malignancies suggests that CBT sensitises tumours to subsequent chemotherapy. We performed the first analysis of CBT on subsequent NHL treatment. Seventeen North American centres retrospectively queried records. The primary aim was to evaluate the overall response rate (ORR) to post-CBT treatment. Secondary aims included progression-free survival (PFS), duration of response (DOR) and overall survival (OS). Fifty-nine patients (68% aggressive NHL, 69% advanced disease) were included. Patients received a median of three therapies before CBT. Fifty-three (90%) discontinued CBT due to progression. Post-CBT regimens included chemotherapy (49%), targeted therapy (30%), clinical trial (17%), transplant conditioning (2%) and chimeric antigen receptor T cell (CAR-T) therapy (2%). The ORR to post-CBT treatment was 51%, with median PFS of 6·1 months. In patients with at least stable disease (SD) to post-CBT, the median DOR was significantly longer than to pre-CBT (310 vs. 79 days, P = 0·005) suggesting sensitisation. Nineteen patients were transplanted after post-CBT therapy. Median overall survival was not reached, nor affected by regimen. Prospective trials are warranted, as this may offer R/R NHL patients a novel therapeutic approach.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Carreau NA, Armand P, Merryman RW, et al. Checkpoint blockade treatment sensitises relapsed/refractory non-Hodgkin lymphoma to subsequent therapy. Br J Haematol. 2020. PMID: 32430944. doi:10.1111/bjh.16756

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。